Literature DB >> 7032932

Adjuvant chemotherapy, anti-estrogen therapy and immunotherapy for stage II breast cancer.

C A Hubay, O H Pearson, J S Marshall, R S Rhodes, S M Debanne, E G Mansour, R E Hermann, J C Jones, W J Flynn, C Eckert, W L McGuire.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 7032932

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0014-2964            Impact factor:   9.162


× No keyword cloud information.
  3 in total

Review 1.  Surgery plus adjuvant chemotherapy--a review of therapeutic implications. I. Breast cancer.

Authors:  S K Carter
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

2.  Adjuvant endocrine therapy, cytotoxic chemotherapy, and immunotherapy in stage-II breast cancer: five-year results.

Authors:  O H Pearson; C A Hubay; J S Marshall; N H Gordon; W L McGuire; E G Mansour; R E Hermann; J C Jones; W J Flynn; C Eckert
Journal:  Breast Cancer Res Treat       Date:  1983       Impact factor: 4.872

3.  Adjuvant therapy of stage II breast cancer: 48-month follow-up of a prospective randomized clinical trial.

Authors:  C A Hubay; O H Pearson; J S Marshall; T A Stellato; R S Rhodes; S M DeBanne; J Rosenblatt; E G Mansour; R E Hermann; J C Jones; W J Flynn; C Eckert; W L McGuire
Journal:  Breast Cancer Res Treat       Date:  1981       Impact factor: 4.872
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.